Marshall Wace North America L.P. - G1 THERAPEUTICS INC ownership

G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 95 filers reported holding G1 THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.

Quarter-by-quarter ownership
Marshall Wace North America L.P. ownership history of G1 THERAPEUTICS INC
ValueSharesWeighting
Q2 2020$316,000
-13.4%
13,003
-5.7%
0.00%0.0%
Q4 2019$365,000
-27.4%
13,793
-15.9%
0.00%
-33.3%
Q2 2019$503,000
+128.6%
16,393
+23.8%
0.00%
+200.0%
Q1 2019$220,000
-87.1%
13,240
-85.1%
0.00%
-93.8%
Q4 2018$1,703,000
+178.3%
88,909
+659.4%
0.02%
+700.0%
Q3 2018$612,00011,7080.00%
Other shareholders
G1 THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 98,482$1,631,0000.60%
Opus Point Partners Management, LLC 20,844$346,0000.47%
HHLR ADVISORS, LTD. 949,431$15,761,0000.44%
Rhenman & Partners Asset Management AB 212,169$3,522,0000.41%
Virtus ETF Advisers LLC 8,654$144,0000.31%
BB BIOTECH AG 671,925$11,154,0000.28%
RA Capital Management 363,051$6,027,0000.26%
BDO Wealth Advisors, LLC 35,234$585,0000.17%
Birchview Capital, LP 15,000$249,0000.16%
SECOR Capital Advisors, LP 37,205$618,0000.13%
View complete list of G1 THERAPEUTICS INC shareholders